About Sermorelin Peptides

Sermorelin Peptides is an independent editorial project that publishes summaries of the peer-reviewed research literature on sermorelin, the GHRH(1-29) analog. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

This site operates as a research-intelligence dashboard: a structured, evidence-rated, citation-indexed surface for the sermorelin literature. Every quantitative claim is sourced to a primary study, prescribing document, or regulatory record. Evidence confidence is rated explicitly — STRONG for FDA-reviewed pediatric RCT data, MODERATE for adult class-level extrapolations, LIMITED for healthy-adult long-term data — so readers can locate the current frontier of the evidence base.

The 'peptides' modifier in the domain name is editorial framing — a position relative to the research literature, not a claim about services offered. No compound is manufactured or sold here. No prescription is written here. The regulatory reality is stated plainly: no FDA-approved sermorelin product exists in the US market as of 2026; Geref was withdrawn in 2008-2009 for commercial reasons, not safety [12]; compounded adult sermorelin is off-label and requires documented medical necessity under 2026 FDA guidance [12]; WADA classifies sermorelin as a prohibited substance under S2 for competitive athletes [20].

sermorelin is a compound with a substantial research record spanning four decades and multiple species. The pediatric GHD record is robust and FDA-reviewed. The adult body composition, sleep, and anti-aging record is class-level — largely extrapolated from related GH secretagogues — with limited sermorelin-specific large RCT data in healthy adults. This dashboard indexes both: confirmed findings and evidence gaps are labeled separately.

Sermorelin Peptides has no affiliation with any pharmaceutical company, compound pharmacy, research-chemical supplier, clinic, or healthcare provider. The site does not link to any commercial vendor of sermorelin or related compounds.

Every editorial decision on this site is governed by one standard: accuracy to the primary literature. When the research record is strong (the Thorner 1996 Geref multicenter pediatric data, the Sigalos 2017 hypogonadal-men IGF-1 study, the GHRH-class tesamorelin meta-analysis), that strength is stated. When the record is limited (healthy-adult anti-aging endpoints, long-term adult sermorelin-specific data), that limitation is stated and the Blackman 2008 'not yet ready for prime time' counterpoint is included alongside the efficacy data.

The five rules that govern our editorial voice: 1. Lead with the measured finding. The hedge follows, in attribution. 2. Attribute after, not before. '10 mcg/kg produced X outcome (Author Year)' — not 'According to Author et al., it was found that...' 3. Reproducible findings are identified plainly as reproducible. 4. Be precise where the data is precise; be honest where it is not. 5. Active, specific sentences. Every sentence earns its place.

This site does not write prescriptive language. It does not recommend human doses. All dosing references are framed in the third person, study-attributed, with species and route specified.